HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada Blasts German Sleep Aid Reverse Switch

Executive Summary

Stada criticizes German switch committee's recommendation to restrict access to first generation antihistamines with a sedative effect for over-65s. 

You may also be interested in...



Stada Wins Battle To Keep Hoggar Night Sleep Aid OTC In Germany

Stada has won a two year battle to keep its Hoggar Night sleep aid (doxylamine) available OTC for German adults aged 65 and older.

Stada Says Lemocin’s OTC Status 'Vindicated' By German Switch Committee Decision

Stada's Lemocin cough lozenges survive a German reverse-switch threat, as does first generation anti-histamine dimenhydrinate, pointing to possible good news for the company's other major German OTC brand, Hoggar Night (doxylamine), which is also having its OTC status re-examined by the country's Expert Committee on Prescription.

Stada Study Debunks German Sleep Aid Reverse-Switch Worries

Ahead of an incoming German reverse-switch ruling, Stada publishes reslts of a study showing no evidence of increased risk of falling in connection with the use of antihistamine-based sleeping pills such as the company’s Hoggar Night brand. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel